Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment Optimization in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma
NCT02881086Phase 3Completed
- Sponsor
- Goethe University Frankfurt
- Start
- Aug 2016
- Primary completion
- Dec 2024
- Modality
- Prodrugs/Conditional Activator Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of nelarabine in acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), sponsored by Goethe University Frankfurt. Started Aug 2016; status: completed.
02
Drugs
nelarabine
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT02881086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02881086.